Antibiotic usage and the development of resistance

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1139-1140

  Fernandes, Prabhavathi ^a   Oldach, David ^a  

^a Active Implementation Research Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; DRUG HALF LIFE; GONORRHEA; HUMAN; IN VIVO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SUSCEPTIBLE POPULATION; DRUG EFFECTS; FEMALE; MALE; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84926628500     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1174     Document Type: Letter

References (3)

1. Kuster SP, Rudnick W, Shigayeva A, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis 2014; 59:944-52.
2. Matzneller P, Krasniqi S, Kinzel M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents Chemother 2013; 57:1736-42.
3. Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?. Antimicrob Agents Chemother 2012; 56: 2739-42.